Cardiol Therapeutics Inc. (CRDL)
CRDL Stock Price Chart
Explore Cardiol Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze CRDL price movements and trends.
CRDL Company Profile
Discover essential business fundamentals and corporate details for Cardiol Therapeutics Inc. (CRDL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
15 Jan 2019
Employees
18.00
Website
https://www.cardiolrx.comCEO
David G. Elsley MBA
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
CRDL Financial Timeline
Browse a chronological timeline of Cardiol Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.10.
Earnings released on 14 Aug 2025
EPS came in at -$0.07 surpassing the estimated -$0.11 by +36.36%.
Earnings released on 13 May 2025
EPS came in at -$0.10 surpassing the estimated -$0.13 by +23.08%.
Earnings released on 31 Mar 2025
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%.
Earnings released on 14 Nov 2024
EPS came in at -$0.13 falling short of the estimated -$0.10 by -30.00%.
Earnings released on 12 Aug 2024
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%.
Earnings released on 14 May 2024
EPS came in at -$0.10 falling short of the estimated -$0.06 by -66.67%.
Earnings released on 26 Mar 2024
EPS came in at -$0.09 matching the estimated -$0.09.
Earnings released on 14 Nov 2023
EPS came in at -$0.07 surpassing the estimated -$0.12 by +41.67%.
Earnings released on 10 Aug 2023
EPS came in at -$0.09 surpassing the estimated -$0.12 by +25.00%.
Earnings released on 15 May 2023
EPS came in at -$0.08 surpassing the estimated -$0.15 by +46.67%.
Earnings released on 28 Mar 2023
EPS came in at -$0.09 falling short of the estimated $0.15 by -160.00%.
Earnings released on 10 Nov 2022
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%.
Earnings released on 10 Aug 2022
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.74%.
Earnings released on 16 May 2022
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 23 Mar 2022
EPS came in at -$0.09 surpassing the estimated -$0.11 by +18.68%.
Earnings released on 15 Nov 2021
EPS came in at -$0.18 .
Earnings released on 17 Aug 2021
EPS came in at -$0.13 , while revenue for the quarter reached $63.54K .
Earnings released on 18 May 2021
EPS came in at -$0.20 .
Earnings released on 31 Dec 2020
EPS came in at -$0.23 .
Earnings released on 12 Nov 2020
EPS came in at -$0.10 .
CRDL Stock Performance
Access detailed CRDL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.